AC Nova Technologies Inc ( aka “ATI Pharma”) Announces the Launch of NutraPause a Botanical Supplement Clinically Shown to Relieve Vasomotor Symptoms (Hot Flashes and Night Sweats) Associated with Perimenopause and Menopause

Tuesday March 15th, 2016  For Immediate Release  Click for full press release



Toronto, Canada and Denver,USA- AC Nova Technologies Inc (aka ATI Pharma), a leader in the development of evidence-based botanical supplements, is pleased to announce the launch of NutraPause for the treatment of vasomotor symptoms associated with Perimenopause and Menopause (NPH 80031417).

NutraPause is now available through Safeway in Western Canada and will also be available in Eastern Canada and throughout the USA through www.atipharma.com online store 

by March, 2016. 

There are approximately 33 million women in the United States and in Canada between the ages of 45-59, and the average age of menopause in the U.S and Canada is 51. Based on survey data, an estimated 50% of postmenopausal women experience vasomotor symptoms.

Traditional Hormone Replacement Therapy (HRT) was the main treatment for menopause for decades. In 2002 findings from a large clinical study called the Women`s Health Study Initiative (WHI) that included 27,000 women raised concerns about the long term safety of HRT. This has led to a search for therapies that do not increase the risk of heart attacks, strokes, blood clots or breast cancers.

The approval of NutraPause is an important, novel, effective and safe alternative therapy to traditional hormone therapies for alleviating those vasomotor symptoms often associated with perimenopause and or menopause. According to Ms. Carmella Angus (Founder and Chairman of the Board of ATI Pharma) “NutraPause presents a new opportunity for women and their doctors and/or other healthcare practitioners to discuss alternative effective and safe treatment options for managing hot flashes and night sweats.” 

Nutrapause has also been reported anecdotally, to increase energy and muscle tone. Click for full press release